Research programme: HIV gene therapy - MolMed/Takara Bio

Drug Profile

Research programme: HIV gene therapy - MolMed/Takara Bio

Alternative Names: Chim3; F12-Vif; MM-F12

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MolMed; Takara Bio
  • Class Gene therapies; Polynucleotides; Proteins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in HIV-infections in Japan (Parenteral)
  • 29 Jun 2009 Preclinical development is ongoing in Japan
  • 29 Jun 2009 Chim3 is available for licensing worldwide (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top